Mar­ket slack­er Cel­gene does some­thing good for a change, look­ing to turn the cor­ner on past mishaps

At this point Cel­gene has been so bat­tered over its poor per­for­mance of the past year you have to do a dou­ble take to con­vince your­self when some­thing good hap­pens to it.

But there was some con­sid­er­able good news to be had in its Phase III study of fran­chise drug Revlim­id in com­bi­na­tion with Roche’s Rit­ux­an in two forms — fol­lic­u­lar and mar­gin­al zone — of in­do­lent lym­phoma. 

Ac­cord­ing to re­searchers, they tracked a “high­ly sta­tis­ti­cal­ly sig­nif­i­cant” im­prove­ment in pro­gres­sion-free sur­vival in the study, open­ing the door to some near-term mar­ket­ing ap­pli­ca­tions that at least one promi­nent an­a­lyst spec­u­lates could be worth more than $1 bil­lion in added sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.